Profound Medical

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (

Post-Stroke Secondary Prevention With Digital Monitoring

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Pa

Polish Version Fatigue Severity Scale

Dilution score: 19/100 (LOW), 24.0 months cash

Short interest: 6.28% of float, squeeze risk: MODERATE

1467 PubMed publications found for Profound Medical

Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation.

From profound hypothermia to malignant hyperpyrexia: a case report of biphasic thermoregulatory crisis following acute high cervical spinal cord injury.

IR783-enabled thioketal-bridged paclitaxel nanoprodrugs with ROS-responsive release for tumor imaging and chemotherapy.

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates.

1466 PubMed publications found for Profound Medical

Design of the MERCURION-IPF trial - intravenous immunoglobulin for the treatment of acute exacerbations of idiopathic pulmonary fibrosis.

Dilution score: 27/100 (MEDIUM), 26.4 months cash

1465 PubMed publications found for Profound Medical

Short interest: 6.67% of float, squeeze risk: MODERATE

1464 PubMed publications found for Profound Medical

Challenging Anticoagulation With Warfarin and Heparin Following Mechanical Mitral Valve Replacement in a Patient With Infective Endocarditis: A Case Report Highlighting Diagnostic Difficulties.

1461 PubMed publications found for Profound Medical

Establishment of an immortalized erythroid model for Hb Bart's hydrops fetalis with homozygous α(0)-thalassemia Southeast Asian deletion.

Case Report: triple therapy with pembrolizumab, ipilimumab, and lenvatinib in mitotane- and radiation-refractory, cortisol-secreting stage IV adrenocortical carcinoma: a genomically guided approach.

Dilution score: 27/100 (MEDIUM), 34.3 months cash

1460 PubMed publications found for Profound Medical

SW convergence: 50/100 (Neutral), 1 bullish / 0 bearish signals

1451 PubMed publications found for Profound Medical

P-CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study.

Beyond attenuation: a translational review of curative-intent pharmacological targets in idiopathic pulmonary fibrosis.

Design, synthesis, and biological evaluation of selective cytotoxicity-derived Miliusol derivatives inducing profound TNBC regression in vivo.

Emerging and Off-Label Uses Of Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) and Dual GIP/GLP1-RAs.

Not All Hemolysis Is Hemolytic: A Case of Pernicious Anemia.

Short interest: 6.01% of float, squeeze risk: MODERATE

1450 PubMed publications found for Profound Medical

Precision oncology in gynecologic cancers: molecular taxonomy, biomarker-guided therapeutics, and the challenge of therapeutic resistance.

1449 PubMed publications found for Profound Medical

Effects of Ciprofol Combined with Varying Doses of Alfentanil on Anesthetic Efficacy and Safety in Pediatric Bronchoscopy: A Randomized Controlled Trial.

1448 PubMed publications found for Profound Medical

Advancing precision medicine in pancreatic cancer using novel biomarkers and clinical targets.

<article class="bts-verified-summary" data-ticker="PROF">
<p>Profound Medical (PROF) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>No Form 4 insider filings for PROF were recorded at the SEC in the past 30 days<sup><a href="#fn-2">[2]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Profound+Medical%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">SEC EDGAR · 0001628808 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22PROF%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR — 0001628808

Profound Medical (PROF) — BioTechSigns Verified Summary

Profound Medical (PROF) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[1].

No Form 4 insider filings for PROF were recorded at the SEC in the past 30 days[2].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Profound+Medical%22&aggFilters=status%3Arec%2Cact
[2] SEC EDGAR, 0001628808. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22PROF%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11

A prospective, multi-center, single-arm study, planned in 150 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system (TULSA-PRO) intended to ablate prostate tissue of patients with localized, organ-confined prostate cancer.

Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer

This patient registry will capture data from patients who have been or who are undergoing the transurethral ultrasound ablation (TULSA) procedure as part of their routine clinical care. The registry will shed light on real-world outcomes of safety and efficacy of the procedure and understand how a patient's quality of life is affected throughout their follow-up and lifetime.

Customized TULSA-PRO Ablation Registry

Men with localized, intermediate risk prostate cancer will be randomized to undergo either radical prostatectomy or the TULSA procedure, with a follow-up of 10 years in this multi-centered randomized control trial. This study will determine whether the TULSA procedure is as effective and more safe compared to radical prostatectomy.